01—Abstract
Summary
Summary of the 10-K filed March 2, 2006. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific Inc. (TMO) reported strong revenue growth in 2005, driven by significant acquisitions and organic demand across its key segments.
The company's strategy of augmenting internal growth with strategic acquisitions has bolstered its presence, particularly in the Life and Laboratory Sciences segment, which saw a substantial increase in sales due to the acquisition of Kendro. The Measurement and Control segment also experienced growth, benefiting from demand in industrial and environmental applications. While the company experienced higher operating income, its operating income margin saw a slight decrease due to increased amortization expenses from acquisition-related intangible assets.
Management is focused on integrating acquired businesses to realize synergies and improve productivity. The company maintains a solid financial position with sufficient liquidity and manages its market risks through operational activities and hedging strategies.
02—Key points
Key Highlights
- Revenue increased by 19% to $2.63 billion in 2005, driven by a 15% contribution from acquisitions and net divestitures, alongside a 4% increase in organic sales.
- The Life and Laboratory Sciences segment experienced a significant revenue jump of 25%, largely due to the acquisition of Kendro Laboratory Products and other strategic acquisitions, complemented by broad-based demand and new product introductions.
- The Measurement and Control segment saw a 6% revenue increase, primarily from higher demand in industrial and environmental/security applications.
- Operating income grew to $263.5 million, though the operating income margin slightly decreased to 10.0% from 10.8% in the prior year, primarily due to $54.8 million in increased amortization of acquisition-related intangible assets.
- Thermo Fisher Scientific completed several key acquisitions in 2005, including Kendro Laboratory Products ($836.6 million), Ionalytics Corporation ($24.7 million), Rupprecht and Patashnick Co., Inc. ($31.0 million), and Niton LLC ($40.9 million), significantly expanding its capabilities and market reach.
- The company continues to invest in research and development, with R&D expenses totaling $152.8 million in 2005, a 13% increase from the previous year.
- Backlog increased to $528.1 million at year-end 2005, up from $467.0 million in 2004, indicating strong future demand, particularly in the Life and Laboratory Sciences segment.
03—Questions
Frequently Asked Questions
What was the primary driver of Thermo Fisher Scientific's revenue growth in 2005?
Thermo Fisher Scientific's revenue grew by 19% to $2.63 billion in 2005. This growth was primarily driven by significant acquisitions, which contributed 15% to the revenue increase, along with a 4% rise in organic sales due to increased demand and pricing.
Which segment performed strongest in terms of revenue growth?
The Life and Laboratory Sciences segment demonstrated the strongest revenue growth, increasing by 25% in 2005. This was largely attributed to the acquisition of Kendro Laboratory Products and other strategic acquisitions, which broadened its product offerings and customer base.
How did the company's profitability fare in 2005?
Operating income increased to $263.5 million in 2005. However, the operating income margin decreased slightly to 10.0% from 10.8% in 2004. This was primarily due to higher amortization expenses of $54.8 million related to acquisition-related intangible assets.
What were the key acquisitions made by Thermo Fisher Scientific in 2005?
In 2005, Thermo Fisher Scientific made several significant acquisitions to expand its market presence and product portfolio. Key acquisitions included Kendro Laboratory Products for $836.6 million, Ionalytics Corporation for $24.7 million, Rupprecht and Patashnick Co., Inc. for $31.0 million, and Niton LLC for $40.9 million.
04—Continue